- Previous Close
1.4300 - Open
1.3800 - Bid 0.9792 x 200
- Ask 1.7200 x 200
- Day's Range
1.3300 - 1.3900 - 52 Week Range
1.3300 - 4.6900 - Volume
85,692 - Avg. Volume
686,225 - Market Cap (intraday)
68.248M - Beta (5Y Monthly) 1.32
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1200 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.14
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. Akoya Biosciences, Inc. was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
www.akoyabio.comRecent News: AKYA
View MorePerformance Overview: AKYA
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AKYA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AKYA
View MoreValuation Measures
Market Cap
71.24M
Enterprise Value
120.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.87
Price/Book (mrq)
9.38
Enterprise Value/Revenue
1.47
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-67.79%
Return on Assets (ttm)
-16.86%
Return on Equity (ttm)
-180.45%
Revenue (ttm)
81.67M
Net Income Avi to Common (ttm)
-55.37M
Diluted EPS (ttm)
-1.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
35.04M
Total Debt/Equity (mrq)
1,107.91%
Levered Free Cash Flow (ttm)
-26.52M